The company “Takeda Russia” announced the receipt of a registration certificate of Ministry of health of the Russian Federation, confirming the right to produce oxazoline for the treatment of patients with multiple myeloma. The production of the drug included in the EDL will be carried out at the company’s plant in Yaroslavl. The total investment in the localization of production totaled 590 million rubles.
The production capacity will meet the demand and EEU in a drug, said the company. The plant in Yaroslavl became the second company in the world for the production of the drug and the stage of the finished dosage form.
Exosomes is a proprietary development of the company, is available in capsule form and is shown in combination with lenalidomide and dexamethasone for patients with multiple myeloma that have previously received at least one line of previous treatment. The drug was registered in Russia in 2017 and launched into the Russian market in 2018.